CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participate in three upcoming conferences.

JMP Securities Life Sciences Conference
Date: May 15^th to May 16^th, 2023
Location: New York, NY

BIO International Convention
Date: June 5^th to June 8^th, 2023
Location: Boston, MA

H.C. Wainwright 1^st Annual Neuropsychiatry Virtual Conference
Date: Monday June 26^th, 2023
Location: Virtual

Webcast information, where available, will be on www.Trevena.com 

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK^® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit www.Trevena.com

For more information, please contact:

Investor Contact:
Dan Ferry - Managing Director
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 
(617) 430-7576

Company Contact:
Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840